Director/PDMR Shareholding - amendment

August 18th 2010

This is a correction of the announcement 2276R from 7.00 on 18.08.2010. Reason for the correction: the number of shares acquired for each director was incorrect. The corrected version is set out below.

Cyprotex PLC ("Cyprotex" or the "Company")

Macclesfield, UK - Cyprotex PLC (LSE: CRX), a Contract Research Organisation (CRO) specialising in the preclinical ADME assessment of drug candidates, was informed on 17 August 2010 that certain directors acquired ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 17 August 2010. Details of the dealings are set out below:

Name	Title	Price	Shares acquired	Total interest following dealing	% of total issued share capital
Steve Harris	Chairman	3.50	707,142	1,507,142	0.67
Anthony Baxter	CEO	3.50	226,285	1,067,685	0.48
John Dootson	CFO	3.50	589,285	589,285	0.26
Katya Tsaioun	CSO	3.50	1,767,857	24,133,006	10.79
Douglas Bates	CMO	3.50	5,303,571	27,668,719	12.37

For further information please contact:

Cyprotex PLC	Tel: +44 1625 505 100
Dr. Anthony Baxter, Chief Executive Officer
a.baxter@cyprotex.com
www.cyprotex.com
Singer Capital Markets Ltd	Tel: +44 203 205 7500
Shaun Dobson
Claes Spång
Financial Dynamics	Tel: +44 207 831 3113
Ben Brewerton
Ben Atwell
Mo Noonan

Director/PDMR Shareholding - amendment

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

or fill out the form below: